- Home
- MBAI vs CRIS Comparison
MBAI vs CRIS Comparison
Compare MBAI & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBAI | CRIS |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | Israel | United States |
| Employees | 85 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 14.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | MBAI | CRIS |
|---|---|---|
| Price | $1.76 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 151.3K | ★ 226.9K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $1.29 | $0.46 |
| 52 Week High | $3.92 | $3.13 |
Technical Indicators
Market Signals| Indicator | MBAI | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 39.91 |
| Support Level | $1.35 | $0.48 |
| Resistance Level | $1.91 | $0.63 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 45.70 | 24.80 |
Price Performance
Historical ComparisonAbout MBAI Check-Cap Ltd. Ordinary Share
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.